The Effect of Problem Solving Therapy and Antidepressant Therapy on Cerebral Perfusion and Brain Derived Neurotropic Factor (BDNF) in Depressed Elders
Major Depressive Disorder
Behavioral: problem solving therapy
|Study Design:||Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||The Effect of Problem Solving Therapy and Antidepressant Therapy on Cerebral Perfusion and Brain Derived Neurotropic Factor in Depressed Elders|
- change in cerebral perfusion [ Time Frame: study endpoint (8-12 weeks) ] [ Designated as safety issue: No ]Change in cerebral perfusion from baseline to study endpoint in frontal brain regions.
- Change in cognitive measures of memory, learning, and executive dysfunction [ Time Frame: Baseline to study endpoint (8-12 weeks) ] [ Designated as safety issue: No ]Change assessed on neuropsychological measures of memory, learning, and executive dysfunction
- Change in BDNF [ Time Frame: 8-12 weeks ] [ Designated as safety issue: No ]Change in BDNF from baseline to endpoint (8-12 weeks)
|Study Start Date:||March 2011|
|Estimated Study Completion Date:||June 2016|
|Estimated Primary Completion Date:||June 2016 (Final data collection date for primary outcome measure)|
Experimental: problem solving therapy
subjects will receive 12 weeks of weekly problem solving therapy
Behavioral: problem solving therapy
12 weeks of weekly 45 minute sessions of problem solving therapy
Other Name: PST
12 weeks of sertraline
12 weeks of sertraline; 25 mg for one week, 50 mg for 3 weeks; then 100 mg/day for 4 weeks; then 150 mg/day for 4 weeks based on tolerability and response
Other Name: SSRI
Hide Detailed Description
Subjects: subjects will have non-psychotic unipolar major depression based on DSM IV criteria (Structured Clinical Interview for DSM IV; SCID)and be 65 years or older and will have depression of moderate or greater depression severity (Hamilton Depression Rating Scale score > or = 19. Depression severity will be assessed with the clinician rated Hamilton Depression Rating Scale (HDRS) and the subject rated Quick Inventory of Depressive Symptoms (QIDS). Ratings will be performed weekly for the first month and then every 2 weeks until the end of the trial.
Neuroimaging: The MRI studies included in this protocol are commonly utilized in clinical practice. In addition to conventional structural MRI, this protocol will utilize techniques developed to evaluate cerebral blood flow (arterial spin labeling), white matter integrity (diffusion tensor imaging), and brain biochemistry (MR spectroscopy) and will be performed using a 4 Tesla magnet. Imaging will be performed at the VAMC/UCSF Center for Imaging of Neurodegenerative Disease (CIND) under the direction of Michael Weiner, M.D. Brain derived neurotropic factor (BDNF): a blood sample will be drawn pretreatment to determine the serum concentration of BDNF. This test will be repeated post-treatment. The assay for BDNF will be performed in the laboratory of Synthia Mellon, Ph.D at UCSF. Serum will be assayed for BDNF in duplicate, using a commercial BDNF ELISA assay kit (R&D Systems, Minneapolis, MN, USA).
Cognition will be assessed with a battery of neuropsychological tests including the Stroop Color-Word Test, the Trail Making Test: A and B; Dementia Rating Scale I/P; Boston Naming Test, and the Hopkins Verbal Learning Test-Short.
Treatment assignment: If patients have a preference for PST or sertraline, they will receive that treatment. If they have no preference, they will be randomized to one or the other until 19 subjects have been assigned to each treatment.
Sertraline, a selective serotonin reuptake inhibitor (SSRI), will be administered as the antidepressant. It will be started at 25 mg/day for one week and then increased to 50 mg and continued for 3 weeks. At the end of 4 weeks if the patient has had limited response, the dose will be increased to 100 mg/day. At 8 weeks if response is limited, dose will be increased to 150 mg/day. At any time, the dose can be lowered for tolerability reasons.
Problem Solving Therapy. Patients receiving PST will be seen weekly for 12 individual 45 minute sessions. Problem Solving Therapy (Arean, Raue, and Julian; UCSF unpublished manuscript, 2003) consists of 12 weekly sessions to teach participants a five-step problem-solving model. This model is taught over the first five weeks of treatment. Subsequent sessions are dedicated to refining PST skills. In the last two PST sessions, participants create a relapse prevention plan using the PST model. There will be two therapists in the study both trained to perform PST and with experience in prior studies of PST for MDD in older adults.
Data will be analyzed by Drs Nelson and Mackin in consultation with Kevin Delucchi, Ph.D.(Department of Biostatistics/Psychiatry; UCSF). All analyses will be performed within treatment groups (psychotherapy or drug treatment) and will compare baseline values with post-treatment values in patients completing at least 8 weeks of treatment. All analyses will begin by graphically and numerically summarizing all measures to assess the distribution of scores. To statistically control for appropriate associations of other demographic variables (such as age, sex, and education) and clinical variables (such as social support, medical comorbidity, physical frailty, and medication use) with the outcome measure, we will use linear regression modeling methods. Missing data, if any, will be carefully described and analyzed. The methodology to be used assuming missing at random (MAR) which is a reasonable assumption for this type of data and the relatively low levels of missing data we anticipate based on prior research with this population. Because we have specific a priori hypotheses regarding BDNF and the composite score for executive dysfunction, we will not correct for multiple comparisons. Analysis of the cerebral blood flow data, however, will employ corrections for multiple comparisons. As stated the aim of the study is to gather preliminary data regarding change from baseline to the study endpoint within the sertraline or within the PST treatment group. Attrition is estimated at 20% allowing for 15 patients to complete each treatment arm.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01305889
|Contact: Ross Crothers||415.476.7046||Ross.Crothers@ucsf.edu|
|Contact: J. Craig Nelson, MD||415 476 firstname.lastname@example.org|
|United States, California|
|Langley Porter Psychiatric Institute||Recruiting|
|San Francisco, California, United States, 94143|
|Principal Investigator: J. Craig Nelson, M.D.|
|Sub-Investigator: R. Scott Mackin, Ph.D.|
|Sub-Investigator: Michael Weiner, M.D.|
|Principal Investigator:||J. Craig Nelson, MD||Univeristy of California San Francisco, Langley Porter Psychiatric Institute|
|Principal Investigator:||R. Scott Mackin, MD||Univeristy of California San Francisco, Langley Porter Psychiatric Institute|